MedTrace Logo

Bitherapy With the Combination of Raltegravir and Darunavir (BIRDi)

NCT03348449 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 360

Last updated 2018-07-02

No results posted yet for this study

Summary

Retrospective cohort of virologically suppressed HIV-infected patients who received the combination of Raltegravir plus Darunavir boosted with cobicistat or ritonavir, as dual therapy, because or toxicity or intolerance to nucleoside analogues

Conditions

Interventions

OTHER

Collection of data

Outcome of patients will be collected from charts to evaluate primary and secondary objectives

Sponsors & Collaborators

  • Merck Sharp & Dohme LLC

    collaborator INDUSTRY

  • Asociacion para el Estudio de las Enfermedades Infecciosas

    lead NETWORK

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-12-15
Primary Completion
2018-06-15
Completion
2018-06-29

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03348449 on ClinicalTrials.gov